Floatz logo

Adebrelimab

Advanced Renal Cell Carcinoma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Advanced Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Trebananib
National Cancer Institute (NCI)
Phase 2BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Telaglenastat
Calithera Biosciences, Inc
Phase 2B
Dfn-15
Case Comprehensive Cancer Center
Phase 2B

View all 32 →

Same molecule, other indications

Adebrelimab is also rated in:

Metastatic Colon CancerDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →